Several investors have recently changed their stakes in Kezar Life Sciences (KZR). Affinity Asset Advisors bought a new position worth $1.59 million. Acadian Asset Management increased its holdings by 42.5% in the first quarter, now owning approximately $1.61 million worth of shares. Acuitas Investments grew its stake by 42.8% in the second quarter, now valued at $592,000, while Marquette Asset Management purchased shares worth around $114,000. Point72 Asia also acquired shares valued at about $63,000. Overall, hedge funds hold 67.90% of the companys stock.
Kezar Life Sciences Stock Decline
NASDAQ:KZR opened at $0.74 on Wednesday, with a market cap of $53.87 million. The stock has a negative price-to-earnings ratio of -0.53 and a low beta of 0.21. Its quick and current ratios are 9.58, with a debt-to-equity ratio of 0.05. The 50-day moving average price is $0.62 and the 200-day average is $0.69. The stock has ranged between $0.52 and $1.14 over the past year.
Kezar Life Sciences reported earnings on August 13, with a loss of $0.28 per share, which exceeded analyst expectations of $0.32. Analysts forecast a loss of -1.2 per share for the current fiscal year.
Analysts Are Neutral
HC Wainwright maintained a neutral rating for Kezar Life Sciences on October 2.
Kezar Life Sciences Overview
Kezar Life Sciences, Inc. focuses on developing new treatments for immune-mediated diseases and cancer in the U.S. Its main product is zetomipzomib (KZR-616), which is currently in advanced clinical trials for several conditions.
Further Reading
- Five stocks we like better than Kezar Life Sciences
- What Investors Need to Know to Beat the Market
- NVIDIAs AI Dominance: Why Analysts Predict Major Upside Ahead
- Ride Out The Recession With These Dividend Kings
- These Stocks Are Using Buybacks to Unlock Big Gains
- EV Stocks and How to Profit from Them
- This Is the Entry Into PepsiCo Youve Been Waiting For
Want to see more hedge fund activity with KZR? Visit HoldingsChannel.com for the latest updates.
Get Daily News & Ratings for Kezar Life Sciences – Enter your email to receive a daily summary of news and analysts’ ratings for Kezar Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
`
